Phenylanine derivatives

Details Phenylanine derivatives Phenylanine derivatives

2007-05-16

2010-11-02

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S331000, C530S327000, C530S328000, C530S329000, C530S330000, C514S002600

Reexamination Certificate

active

07825216

ABSTRACT:
The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA)n-Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or more substituents, e.g., hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy, dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and phosphonoalkyl, or phosphonohaloalkyl; W is a moiety attached to the nitrogen of Y and is, e.g., alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl, or alkoxyoxalyl; AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and Z is an arylalkylamino or arylheterocyclyl alkylamino; or a salt thereof; with the proviso that W is not arylalkylamino when the phenyl ring of phenylalanyl contains a phosphonoalkyl or phosphonohaloalkyl substituent at a position para to the alkylamido group and the ortho and meta positions are unsubstituted. The present invention further provides precursors suitable for preparing the phenylalanine derivatives and a method for the preparation of the precursors. The present invention further provides conjugates comprising a precursor and a conjugant that are covalently linked. These conjugates have biological and/or pharmacological properties.

REFERENCES:
patent: 3906031 (1975-09-01), Carpino et al.
patent: 4394519 (1983-07-01), Carpino et al.
patent: 4879398 (1989-11-01), Getman et al.
patent: 5182263 (1993-01-01), Danho et al.
patent: 5200546 (1993-04-01), Burke, Jr. et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5296608 (1994-03-01), Danho et al.
patent: 5369110 (1994-11-01), Schmidlin et al.
patent: 5457114 (1995-10-01), Stüber et al.
patent: 5463062 (1995-10-01), Hemmerle et al.
patent: 5491253 (1996-02-01), Stuk et al.
patent: 5508437 (1996-04-01), Danho et al.
patent: 5525733 (1996-06-01), Novack et al.
patent: 5580979 (1996-12-01), Bachovchin
patent: 5587372 (1996-12-01), Aszodi et al.
patent: 5612370 (1997-03-01), Atwal
patent: 5616776 (1997-04-01), Stuk et al.
patent: 5627283 (1997-05-01), Stüber et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5679842 (1997-10-01), Kleiner
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5688992 (1997-11-01), Burke, Jr. et al.
patent: 5698731 (1997-12-01), Bosetti et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5710173 (1998-01-01), Tang et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5753687 (1998-05-01), Mjalli et al.
patent: 5756817 (1998-05-01), Choi et al.
patent: 5773411 (1998-06-01), Wells et al.
patent: 5780496 (1998-07-01), Tang et al.
patent: 5786454 (1998-07-01), Waksman et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5824862 (1998-10-01), Hiyoshi et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5843997 (1998-12-01), Heinz et al.
patent: 5849510 (1998-12-01), Al-Obeidi et al.
patent: 5849693 (1998-12-01), Wells et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886195 (1999-03-01), Tang et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5922697 (1999-07-01), Lunney et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5948658 (1999-09-01), Landry
patent: 5958957 (1999-09-01), Andersen et al.
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 5981569 (1999-11-01), App et al.
patent: 5981755 (1999-11-01), Horwell et al.
patent: 6022696 (2000-02-01), Harding et al.
patent: 6037134 (2000-03-01), Margolis
patent: 6228986 (2001-05-01), Lanter et al.
patent: 6307090 (2001-10-01), Burke, Jr. et al.
patent: 6410585 (2002-06-01), Larsen et al.
patent: WO 94/07913 (1994-04-01), None
patent: WO 95/11917 (1995-05-01), None
patent: WO 96/23813 (1996-08-01), None
patent: WO 97/08193 (1997-03-01), None
patent: 97/12903 (1997-04-01), None
patent: WO 98/50421 (1998-11-01), None
patent: WO 99/11606 (1999-03-01), None
patent: 00/53583 (2000-09-01), None
patent: WO 00/73326 (2000-12-01), None
Allen et al., “Tritiated Peptides, Part 15. Synthesis of Tritium Labeled Biologically Active Analogues of Somatostatin,”J. Chem. Soc., 1, 989-1003 (1986).
Bardelli, “Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis,”Oncogene, 18, 1139-1146 (1999).
Ben-Levy et al., “A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway,”EMBO J., 13, 3302-3311 (1994).
Bobko et al., “CD45 Protein . . . Irreversible Inhibitors,”Bioorganic&Medicinal Chem. Letters., 5 (4), 353-356 (1995).
Boutin, “Tyrosine Protein Kinase Inhibition and Cancer,”Int. J. Biochem., 26, 1203-1226 (1994).
Burke et al., “Conformationally Constrained . . . 2 Domain Inhibitors”,J. Med. Chem., 38, 1386-1396 (1995).
Burke, Jr. et al., “Nonhydrolyzable Phosphotyrosyl Mimetics for the Preparation of Phosphatase-Resistance SH2 Domain Inhibitors,”Biochemistry, 33, 6490-6494 (1994).
Burke, Jr. et al., “Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors,”Bioorganic&Medicinal Chemistry Letters, 9, 347-352 (1999).
Burke, Jr. et al., “Protein-Tyrosine Phosphatases: Structure, Mechanism, and Inhibitor Discovery”,Biopolymers(Peptide Science), 47, 225-241 (1998).
Burke, Jr. et al., “Phosphotyrosyl-Based Motifs in the Structure-Based Design of Protein-Tyrosine Kinase-Dependent Signal Transduction Inhibitors,”Current Pharmaceutical Design, 3, 291-304 (1997).
Burke, Jr. et al., “Potent Inhibition of Grb2 SH2 domain Binding by Non-Phosphate containing Ligands,”First Annual Meeting on the Experimental Therapeutics of Human Cancer, Jun. 11-13 (1998) (Summary).
Burke, Jr. et al., “4′-O-[2-(2-fluoromalonyl)]L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides,”J. Med. Chem., 39, 1021-1027 (1996).
Burke, Jr. et al., “Preparation of Fluoro- and Hydroxy-4 (phosphonomethyl)-D, L-phenylalanine Suitability Protected for Solid-Phase Synthesis of Peptides Containing Hydrolytically Stable Analogues of O-Phosphotyrosine”,J. of Organic Chemistry, 1336-1340 (1993).
Burke, Jr. et al., “Preparation of . . . Peptide Synthesis,”J. Synthetic Organic Chem., 11, 1019 (1991).
Burke, Jr. et al., “Synthesis of 4-Phosphono(difluoromethyl)-D, L-phenyllanine and N-Boc and N-Fmoc Derivatives Suitability Protected for solid-Phase Synthesis of Nonhydrolyzable Phosphotyrosyl Peptide Analogues”,Tetrahedron Letters, 34, 4125-4128 (1993).
Burke, Jr. et al., “Enantioselective Synthesis . . . Inhibitory Peptides,”Tetrahedron, 54, 9981-9994 (1998).
Charifson et al., “Peptide Ligands of pp60C-STCSH2 Domains: A Thermodynamic and Structural Study,”Biochemistry, 36, 6283-6293 (1997).
Chemical Abstracts, 122, 424 (1995) (Abs. No. 258899).
Chemical Abstracts, “Synthesis and . . . containing peptides”, 123, 1220 (1995) (Abs. No. 257331h).
Chemical Abstracts, 124, 1004 (1996) (Abs. No. 9413).
Chen et al., “Crystal Structore of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA”,Cell, 93, 827-839 (1998).
Cleland, “The Meerwin Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Airlines,”Journal of Organic Chemistry, 34, 744-747 (1969).
Dankort et al., “Distinct Tyrosine Autophosphorylation Sites Negatively and Positively Modulate New-Mediated Transformation”

Affiliated with

Also associated with

Rating

Phenylanine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenylanine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylanine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4172594